Dosing is limited to the inhalation route. This restricts its usage, as treating asthmatics could induce bronchospasms. In 2006 the Food and Drug Administration (FDA) found that breathing problems (bronchospasm), including deaths, were reported in some patients after the initial approval of Relenza. Most of these patients had asthma or chronic obstructive pulmonary disease. Relenza therefore was not recommended for treatment or prophylaxis of seasonal influenza in individuals with asthma or chronic obstructive pulmonary disease. In 2009 the<unk>  package insert contains precautionary information regarding risk of bronchospasm in patients with respiratory disease. GlaxoSmithKline (GSK) and FDA notified healthcare professionals of a report of the death of a patient with influenza having received<unk>  inhalation powder, which was solubilized and administered by mechanical ventilation. In adults there was no increased risk of reported adverse events in trials. There was little evidence of the possible harms associated with the treatment of children with<unk> .<unk>  has not been known to cause toxic effects and has low systemic exposure to the human body.
Zanamivir
Oseltamivir
Peramivir
Quifenadine
Inadine
Rimantadine
Umifenovir
Faricimab